ASX IPO watch: Aspiring healthcare stock has attracted former Macquarie CEO to invest

And former federal health minister Greg Hunt is a board director.

A woman stares at a computer with her face just inches from the screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

An Australian biotech that counts former Macquarie Group Ltd (ASX: MQG) CEO Allan Moss and Platinum Asset Management fund among its shareholders is planning an ASX initial public offering (IPO) next year.

According to The Australian, HaemaLogiX has hired Jefferies and Ord Minnett to assist in its preparations to become an ASX healthcare stock in the second quarter of the new year.

The biotech hopes to raise about $50 million in the ASX IPO.

As a private company, HaemaLogiX has previously raised $24.1 million. It is currently undertaking a pre-ASX IPO capital raise. It hopes to raise between $15 million and $20 million by mid-December.

What is HaemaLogiX?

The company focuses on treating blood cancers, such as myeloma. Its aim is to improve the quality of life and survivability of patients with these incurable diseases.

Myeloma, also known as multiple myeloma, is a type of bone marrow cancer. Myeloma Australia estimates there are 18,000 Australians living with it today.

HaemaLogiX is working with the Peter MacCallum Cancer Centre to undertake the first human trial of its CAR-T immunotherapy, KMA.CAR-T, for kappa-type multiple myeloma.

The organisations hope that the first patient will be treated in the second quarter of 2025.

HaemaLogiX is also investigating the use of its medicines for auto-immune diseases, such as amyloidosis.

The proceeds of this next capital raising will be used for the fourth clinical trial of HaemaLogiX's KappaMab immunotherapy drug.

KappaMab can be used in addition to existing treatments. In the latest trial, the overall response rate was 83%. The risk of death was 46% lower in the treatment group compared to the control group.

Who's in charge of this aspiring ASX healthcare stock?

The company's founders and majority shareholders are Dr Rosanne Dunn; Bryce Carmine; board chair Dr John Cullity and Alan Liddle.

Former federal health minister Greg Hunt is a board director.

HaemaLogiX's managing director is Damian Clarke-Bruce, who previously ran Race Oncology Ltd (ASX: RAC). Race is another ASX biotech developing drugs to treat various cancers.

Clarke-Bruce said:

We have two distinct vehicles and our drugs and our target are significantly differentiated from what's on the market.

We're confident that we will have good efficacy with an excellent safety profile … this is great translational science.

HaemaLogiX says it currently has 75 patent filings with tenures from 2036 to 2045.

ASX IPOs in 2024

Two of the biggest ASX IPOs this year were Mexican restaurant chain, Guzman y Gomez Ltd (ASX: GYG), which raised $335 million, and miner Metals Acquisition CDI (ASX: MAC), which raised $325 million.

This week, payments company Cuscal Ltd (ASX: CCL) had its ASX IPO.

Next month, alternative asset manager HMC Capital Ltd (ASX: HMC)'s will float its data centre trust, DigiCo Infrastructure REIT.

The real estate investment trust (REIT) will float on 12 December.

The ASX IPO issue price will be $5 per share and HMC hopes to raise about $2 billion.

Motley Fool contributor Bronwyn Allen has positions in Macquarie Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended HMC Capital and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended HMC Capital. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »